Brief: Ascelia Pharma Announces Successful Final Results

Ascelia Pharma AB

28/09/2022 09:38

Sept 28 (Reuters) - Ascelia Pharma AB  ACELP.ST :
    * ANNOUNCES SUCCESSFUL FINAL RESULTS FROM ORVIGLANCE HEPATIC
IMPAIRMENT STUDY
    * LEAD DRUG CANDIDATE, MAGNETIC RESONANCE IMAGING (MRI)
CONTRAST
AGENT ORVIGLANCE®, IS WELL TOLERATED IN PATIENTS WITH HEPATIC
IMPAIRMENT
    * DATA CONFIRMED THERE WAS NO RENAL EXCRETION OF ORVIGLANCE,
AND
THAT EXCRETION IS PRIMARILY OCCURRING VIA LIVER ALSO IN THIS
SUBGROUP OF PATIENTS

Source text for Eikon:  ID:nMFN7PrZxw 
Further company coverage:  ACELP.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))